CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

The trial reached its target of 135 LimiFlex patients enrolled into the investigational arm of the trial in December 2019 and the control arm has achieved its target of 160 patients.  To date, a total of 168 study subjects have reached 12 months follow up. 

Amidst this global crisis, innovative hospitals across the United States and Canada are leveraging a new respiratory monitoring system, the MediPines AGM100®.

The study found that the REPAIR Perio protocol had shorter procedure times than open flap procedures, as well as less bruising, swelling, and post-operative bleeding, demonstrating that REPAIR is as effective as open flap procedures in clinical parameters, such as pocket depth and attachment level, but with significantly better patient-reported outcomes.

The objectives of this prospective, randomized, single-blind multicenter study are to demonstrate the safety and efficacy o SELUTION SLR™ 014 DEB n the treatment of ISR with either drug-eluting or bare-metal stents. The study will support the submission for FDA approval.

This study will focus specifically on anterior teeth located in the aesthetic or "smile" region where the loss of a tooth is highly visible.

Published in the Journal of NeuroInterventional Surgery (JNIS) this month, the findings demonstrates how use of the 3D printed aneurysm models for pre-procedural rehearsal allows physicians to rehearse for procedures more accurately and reliably.

The abstracts, published in the June supplement of the Journal of Cystic Fibrosis, were originally submitted to the 2020 European Cystic Fibrosis Conference in Lyon, France, prior to its cancellation.

Sonata demonstrates significant advantages in reducing procedure time, length of stay and procedure-related costs compared to myomectomy.

The one-year results, which successfully demonstrated sustained improvement in Rutherford category, toe-brachial index (TBI) and quality-of-life metrics following management of patients with post-PTA dissection with the Tack Endovascular System® (4F), in conjunction with excellent limb salvage and amputation free survival rates.